Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Nicholas Morrell | M | 62 |
Morphogen-IX Ltd.
 Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | 9 jaar |
| David Grainger | M | 58 |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | 9 jaar |
| Kevin Johnson | M | 64 |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Anne Dobree | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Robert Tansley | M | 61 |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Anton Noordegraaf | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Martin Wilkins | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
| Mark Toshner | M | - |
Morphogen-IX Ltd.
Morphogen-IX Ltd. Miscellaneous Commercial ServicesCommercial Services Morphogen-IX Ltd. operates as a biotechnology company. It develops bone morphogenetic proteins as a novel therapy for the treatment of Pulmonary Arterial Hypertension. The company was founded in 2015 and is headquartered in Babraham, the United Kingdom. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigd Koninkrijk | 8 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Marc Humbert
- Persoonlijk netwerk
